The DEA’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while adult-use marijuana remained in Schedule I. An administrative hearing on broader rescheduling concluded in mid-July 2026, after which the DEA filed a closing brief asserting that marijuana “can no longer remain in Schedule I” based on HHS and FDA findings of accepted medical use. The presiding administrative law judge’s recommendation is still pending. On September 9, 2026, the D.C. Circuit rejected challenges seeking to block the April order, allowing the partial Schedule III placement to stand during further litigation. Traders assessing timelines for full rescheduling by year-end weigh the remaining administrative steps, potential court delays, and any administration directives against historical DEA rulemaking durations.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日$809,982 Vol.
2026/09/30
9月30日
3%
12月31日
15%
$809,982 Vol.
9月30日
$679 Vol.
3%
12月31日
$199,733 Vol.
15%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while adult-use marijuana remained in Schedule I. An administrative hearing on broader rescheduling concluded in mid-July 2026, after which the DEA filed a closing brief asserting that marijuana “can no longer remain in Schedule I” based on HHS and FDA findings of accepted medical use. The presiding administrative law judge’s recommendation is still pending. On September 9, 2026, the D.C. Circuit rejected challenges seeking to block the April order, allowing the partial Schedule III placement to stand during further litigation. Traders assessing timelines for full rescheduling by year-end weigh the remaining administrative steps, potential court delays, and any administration directives against historical DEA rulemaking durations.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
マーケット開始日： Jul 31, 2026, 5:46 PM ET
音量
$809,982終了日
2027/01/01マーケット開始日
Jul 31, 2026, 5:46 PM ETリゾルバー
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while adult-use marijuana remained in Schedule I. An administrative hearing on broader rescheduling concluded in mid-July 2026, after which the DEA filed a closing brief asserting that marijuana “can no longer remain in Schedule I” based on HHS and FDA findings of accepted medical use. The presiding administrative law judge’s recommendation is still pending. On September 9, 2026, the D.C. Circuit rejected challenges seeking to block the April order, allowing the partial Schedule III placement to stand during further litigation. Traders assessing timelines for full rescheduling by year-end weigh the remaining administrative steps, potential court delays, and any administration directives against historical DEA rulemaking durations.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
音量
$809,982終了日
2027/01/01マーケット開始日
Jul 31, 2026, 5:46 PM ETリゾルバー
0x65070BE91...The DEA’s April 2026 final order moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III, while adult-use marijuana remained in Schedule I. An administrative hearing on broader rescheduling concluded in mid-July 2026, after which the DEA filed a closing brief asserting that marijuana “can no longer remain in Schedule I” based on HHS and FDA findings of accepted medical use. The presiding administrative law judge’s recommendation is still pending. On September 9, 2026, the D.C. Circuit rejected challenges seeking to block the April order, allowing the partial Schedule III placement to stand during further litigation. Traders assessing timelines for full rescheduling by year-end weigh the remaining administrative steps, potential court delays, and any administration directives against historical DEA rulemaking durations.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問